Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

492 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The effects of pemafibrate and omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study).
Takeda Y, Sakuma I, Hiramitsu S, Okada M, Ueda S, Sakurai M. Takeda Y, et al. Among authors: sakuma i. Front Cardiovasc Med. 2023 Jan 25;10:1094100. doi: 10.3389/fcvm.2023.1094100. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 36760560 Free PMC article.
Corrigendum: The effects of pemafibrate and Omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study).
Takeda Y, Sakuma I, Hiramitsu S, Okada M, Ueda S, Sakurai M. Takeda Y, et al. Among authors: sakuma i. Front Cardiovasc Med. 2023 Mar 16;10:1172664. doi: 10.3389/fcvm.2023.1172664. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37008309 Free PMC article.
Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study).
Sugawara M, Fukuda M, Sakuma I, Wakasa Y, Funayama H, Kondo A, Itabashi N, Maruyama Y, Kamiyama T, Utsunomiya Y, Yamauchi A, Yoshii H, Yamada H, Mochizuki K; J-SELECT study investigators. Sugawara M, et al. Among authors: sakuma i. Diabetes Ther. 2023 Sep;14(9):1517-1535. doi: 10.1007/s13300-023-01438-w. Epub 2023 Jul 6. Diabetes Ther. 2023. PMID: 37410308 Free PMC article.
DAPagliflozin for the attenuation of albuminuria in Patients with hEaRt failure and type 2 diabetes (DAPPER study): a multicentre, randomised, open-label, parallel-group, standard treatment-controlled trial.
Yoshihara F, Imazu M, Sakuma I, Hiroi Y, Hara H, Okazaki O, Ishiguro C, Izumi C, Noguchi T, Shiraiwa T, Nishioka N, Fujii K, Iwakura K, Tomonaga O, Kobayashi K, Takihata M, Yumoto K, Takase H, Himi T, Shimizu I, Murakami T, Wagatsuma K, Sato K, Hiramatsu T, Akabame S, Hata S, Asakura M, Kawabata T, Omae K, Ito S, Kitakaze M; DAPPER Investigators. Yoshihara F, et al. Among authors: sakuma i. EClinicalMedicine. 2023 Nov 27;66:102334. doi: 10.1016/j.eclinm.2023.102334. eCollection 2023 Dec. EClinicalMedicine. 2023. PMID: 38192595 Free PMC article.
Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study.
Nomoto H, Kito K, Iesaka H, Oe Y, Kawata S, Tsuchida K, Yanagiya S, Miya A, Kameda H, Cho KY, Sakuma I, Manda N, Nakamura A, Atsumi T. Nomoto H, et al. Among authors: sakuma i. Pharmaceutics. 2023 Jun 27;15(7):1838. doi: 10.3390/pharmaceutics15071838. Pharmaceutics. 2023. PMID: 37514025 Free PMC article.
Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events.
Sakuma M, Iimuro S, Shinozaki T, Kimura T, Nakagawa Y, Ozaki Y, Iwata H, Miyauchi K, Daida H, Suwa S, Sakuma I, Nishihata Y, Saito Y, Ogawa H, Matsuzaki M, Ohashi Y, Taguchi I, Toyoda S, Inoue T, Nagai R. Sakuma M, et al. Among authors: sakuma i. BMC Med. 2022 Nov 14;20(1):441. doi: 10.1186/s12916-022-02633-5. BMC Med. 2022. PMID: 36372869 Free PMC article. Clinical Trial.
Differential prediction of high-sensitivity cardiac troponin-I, but not N-terminal pro-brain natriuretic peptide, in different pitavastatin doses on cardiovascular events in stable coronary artery disease.
Mitsutake Y, Ishii J, Fukumoto Y, Ito S, Kashiwabara K, Uemura K, Matsuyama Y, Sugiyama Y, Ozaki Y, Iimuro S, Iwata H, Sakuma I, Nakagawa Y, Hibi K, Hiro T, Hokimoto S, Miyauchi K, Daida H, Shimokawa H, Saito Y, Kimura T, Matsuzaki M, Nagai R. Mitsutake Y, et al. Among authors: sakuma i. Int J Cardiol. 2023 Sep 15;387:131138. doi: 10.1016/j.ijcard.2023.131138. Epub 2023 Jun 22. Int J Cardiol. 2023. PMID: 37355235 Free article. Clinical Trial.
Residual Coronary Risk Factors Associated With Long-Term Clinical Outcomes in Patients With Coronary Artery Disease Treated With High- vs. Low-Dose Statin Therapy　- REAL-CAD Substudy.
Higuma T, Akashi YJ, Fukumoto Y, Obara H, Kakuma T, Asaumi Y, Yasuda S, Sakuma I, Daida H, Shimokawa H, Kimura T, Iimuro S, Nagai R. Higuma T, et al. Among authors: sakuma i. Circ J. 2024 May 24;88(6):995-1003. doi: 10.1253/circj.CJ-23-0134. Epub 2023 Jul 21. Circ J. 2024. PMID: 37482412 Free article.
492 results